

Economic Plan

This document identifies the areas prioritised for de Novo economic analysis. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline

1 Guideline

Headaches: the management of Headaches

2 List of Modelling Questions

Clinical questions by scope area	Acute pharmacological treatment of primary headaches
Population	Patients experiencing an acute episode of migraine, tension headache or cluster headache.
Interventions considered for inclusion	<p>Cluster headache:</p> <ul style="list-style-type: none"> - Aspirin - Paracetamol - Oxygen - Triptans - Ergotamine/dihydroergotamine - NSAIDs - Opioids <p>Migraine:</p> <ul style="list-style-type: none"> - Anti emetics - Paracetamol - NSAIDs - Opioids (weak) - Opioids (strong) - Triptans - Ergotamine/dihydroergotamine - Corticosteroids <p>Tension type headaches:</p> <ul style="list-style-type: none"> - Paracetamol - NSAIDs - Opioids (weak) - Opioids (strong) - No treatment

Type of analysis	Cost utility analysis
Clinical questions by scope area	To determine the most cost effective drug treatment for prophylactic pharmacological treatment of primary headaches
Population	Patients experiencing regular episodes of migraine, tension headache or cluster headache.
Interventions considered for inclusion	<p>Cluster headache:</p> <ul style="list-style-type: none"> - CA++ channel blockers - Corticosteroids - Melatonin - Lithium - Anticonvulsants - Serotonergic modulators <p>Migraine:</p> <ul style="list-style-type: none"> - ACE inhibitors or ARBs - SNRIs - SSRIs - Tricyclics - Beta blockers - Calcium channel blockers - Anticonvulsants - Serotonergic modulators <p>Tension type headaches:</p> <ul style="list-style-type: none"> - ACE inhibitors or ARBs - SNRIs - SSRIs - Tricyclics - Beta blockers - Calcium channel blockers - Anticonvulsants
Type of analysis	Cost utility analysis